December 10, 2018


Tildrakizumab-asmn Now Available for Moderate-to-Severe Plaque Psoriasis
Jennifer Barrett, Associate Editor
Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults with plaque psoriasis who are candidates for systemic therapy or phototherapy. 
FDA Approves Dupilumab Add-on for Moderate-to-Severe Asthma
Kristen Coppock, MA, Editor
Dupixent approved as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older.
Talazoparib Approved by FDA for HER2-Negative Breast Cancer
Jennifer Barrett, Associate Editor
Talazoparib is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer.
Ocrelizumab Shows Superior Outcomes in Multiple Sclerosis
Cecilia Pessoa Gingerich
Patients with multiple sclerosis who began treatment with ocrelizumab 2 years earlier had significant reductions in 24-week confirmed disability progression compared to patients who switched from interferon beta-1a.
FDA Approves Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
Jennifer Barrett, Associate Editor
Inotersen is the first FDA-approved RNA-targeting therapeutic that reduces production of the transthyretin protein through a once-weekly subcutaneous injection.
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us